EP2385114A4 - Diagnosis of treatment of cancer using anti-tm4sf20 antibody - Google Patents
Diagnosis of treatment of cancer using anti-tm4sf20 antibodyInfo
- Publication number
- EP2385114A4 EP2385114A4 EP09834500A EP09834500A EP2385114A4 EP 2385114 A4 EP2385114 A4 EP 2385114A4 EP 09834500 A EP09834500 A EP 09834500A EP 09834500 A EP09834500 A EP 09834500A EP 2385114 A4 EP2385114 A4 EP 2385114A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tm4sf20
- diagnosis
- antibody
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008330487 | 2008-12-25 | ||
PCT/JP2009/007237 WO2010073694A1 (en) | 2008-12-25 | 2009-12-25 | Diagnosis of treatment of cancer using anti-tm4sf20 antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2385114A1 EP2385114A1 (en) | 2011-11-09 |
EP2385114A4 true EP2385114A4 (en) | 2012-08-08 |
Family
ID=42287327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09834500A Withdrawn EP2385114A4 (en) | 2008-12-25 | 2009-12-25 | Diagnosis of treatment of cancer using anti-tm4sf20 antibody |
Country Status (4)
Country | Link |
---|---|
US (1) | US9139647B2 (en) |
EP (1) | EP2385114A4 (en) |
JP (2) | JP6009733B2 (en) |
WO (1) | WO2010073694A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2806381C (en) * | 2010-08-13 | 2019-11-05 | Joshua Labaer | Biomarkers for the early detection of breast cancer |
CN105377895B (en) * | 2013-02-26 | 2019-07-05 | 翰林大学校产学协力团 | Antibody for 4 superfamily member of cross-film, 5 albumen includes its anti-cancer composition |
EP3006564B1 (en) * | 2013-05-24 | 2019-10-02 | Saitama Medical University | New peptide and application thereof |
CA2924343A1 (en) | 2013-09-17 | 2015-03-26 | Bolt Threads, Inc. | Methods and compositions for synthesizing improved silk fibers |
US10040862B2 (en) | 2014-04-18 | 2018-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD99 |
US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
KR101836392B1 (en) * | 2016-08-17 | 2018-03-08 | 한림대학교 산학협력단 | A vaccine composition comprising cyclic peptide, an antibody against the cyclic peptide and an anticancer compositions comprising the same |
CN110121504A (en) | 2016-09-14 | 2019-08-13 | 保尔特纺织品公司 | Long homogeneous recombinant fiber protein |
WO2019046338A1 (en) * | 2017-08-28 | 2019-03-07 | Angiex, Inc. | Anti-tm4sf1 antibodies and methods of using same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006132788A2 (en) * | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPS6459878A (en) | 1987-08-31 | 1989-03-07 | Matsushita Electric Ind Co Ltd | Semiconductor laser protective circuit |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
JPH07509137A (en) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | Production of xenoantibodies |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
WO1999063088A2 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
DK2180007T4 (en) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity |
JP2004516802A (en) | 1998-06-02 | 2004-06-10 | ジェネンテック・インコーポレーテッド | Membrane-bound proteins and nucleic acids encoding the same |
US20030190669A1 (en) * | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
US20060160186A1 (en) | 1999-12-09 | 2006-07-20 | Eaton Dan L | Nucleic acid underexpressed in stomach tumor and lung tumor |
MXPA03002974A (en) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Cells producing antibody compositions. |
US7229960B2 (en) * | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
AU2003242024A1 (en) | 2002-06-05 | 2003-12-22 | Chugai Seiyaku Kabushiki Kaisha | Method of constructing antibody |
JP2007020155A (en) | 2005-06-08 | 2007-01-25 | Canon Inc | Image processing apparatus, method, and program, and storage medium |
JP4520951B2 (en) | 2006-02-07 | 2010-08-11 | リッチランド・バイオ・メディカル株式会社 | Insulin secretion inducer and insulin secretion induction composition |
ATE504647T1 (en) | 2007-01-30 | 2011-04-15 | Forerunner Pharma Res Co Ltd | CHIMERIC FC GAMMA RECEPTOR AND METHOD FOR DETERMINING ADCC ACTIVITY USING THE RECEPTOR |
-
2009
- 2009-12-25 EP EP09834500A patent/EP2385114A4/en not_active Withdrawn
- 2009-12-25 JP JP2010543906A patent/JP6009733B2/en active Active
- 2009-12-25 WO PCT/JP2009/007237 patent/WO2010073694A1/en active Application Filing
- 2009-12-25 US US13/138,014 patent/US9139647B2/en active Active
-
2015
- 2015-04-06 JP JP2015077950A patent/JP2015164923A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006132788A2 (en) * | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
Non-Patent Citations (5)
Title |
---|
DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169 - 179, XP004070292, ISSN: 1380-2933, DOI: 10.1016/S1380-2933(96)00045-0 * |
HEVEL JOAN M ET AL: "Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions", BMC GENOMICS, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 7 August 2008 (2008-08-07), pages 376, XP021042116, ISSN: 1471-2164, DOI: 10.1186/1471-2164-9-376 * |
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2003.08.007 * |
MARCEL HULST ET AL: "Early transcriptional response in the jejunum of germ-free piglets after oral infection with virulent rotavirus", ARCHIVES OF VIROLOGY ; OFFICIAL JOURNAL OF THE VIROLOGY DIVISIONOF THE INTERNATIONAL UNION OF MICROBIOLOGICAL SOCIETIES, SPRINGER-VERLAG, VI, vol. 153, no. 7, 4 June 2008 (2008-06-04), pages 1311 - 1322, XP019634074, ISSN: 1432-8798 * |
See also references of WO2010073694A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010073694A1 (en) | 2010-07-01 |
JPWO2010073694A1 (en) | 2012-06-07 |
EP2385114A1 (en) | 2011-11-09 |
US9139647B2 (en) | 2015-09-22 |
JP6009733B2 (en) | 2016-10-19 |
US20120004117A1 (en) | 2012-01-05 |
JP2015164923A (en) | 2015-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253579A1 (en) | Monoclonal anti-gt468 antibodies for treatment of cancer | |
EP2216344A4 (en) | Diagnosis and treatment of cancer using anti-gpr49 antibody | |
PT2426148E (en) | Anti-il-3ra antibody for use in treatment of blood tumor | |
IL225386A0 (en) | Diagnosis and treatment of cancer using anti-ereg antibody | |
EP2417984A4 (en) | Method for treatment of blood tumor using anti-tim-3 antibody | |
EP2373815A4 (en) | Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
EP2050466A4 (en) | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody | |
EP2385114A4 (en) | Diagnosis of treatment of cancer using anti-tm4sf20 antibody | |
GB0922085D0 (en) | Cancer diagnosis and treatment | |
HRP20150007T8 (en) | Treatment of tumors using specific anti-l1 antibody | |
EP2340851A4 (en) | Diagnosis method and therapeutic method for cancer | |
EP2377891A4 (en) | Diagnosis and treatment of cancer using anti-lgr7 antibody | |
EP2420515A4 (en) | Diagnosis and treatment of cancer using anti-tmprss11e antibody | |
IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
EP2331130A4 (en) | Ige antibodies for the treatment of cancer | |
EP2361317A4 (en) | Use of eif3m for the diagnosis and treatment of cancer | |
GB0901837D0 (en) | Cancer diagnosis and treatment | |
EP2123676A4 (en) | Diagnosis and treatment of cancer by using anti-prg-3 antibody | |
EP2214485A4 (en) | Methods for treatment of cancer | |
GB0819543D0 (en) | Treatment of proteostatic disease | |
GB0817859D0 (en) | Treatment of proteostatic disease | |
GB0907098D0 (en) | Cancer treatment and diagnosis | |
GB0817056D0 (en) | Polypeptide for treatment of cancer | |
GB0712513D0 (en) | Treatment of cancer | |
GB0813361D0 (en) | Treatment of cancer fatigue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110704 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120706 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/30 20060101ALI20120702BHEP Ipc: G01N 33/574 20060101ALI20120702BHEP Ipc: A61K 39/395 20060101ALI20120702BHEP Ipc: C07K 16/28 20060101AFI20120702BHEP Ipc: C12N 15/09 20060101ALI20120702BHEP Ipc: C12P 21/08 20060101ALI20120702BHEP Ipc: A61P 35/00 20060101ALI20120702BHEP |
|
17Q | First examination report despatched |
Effective date: 20150123 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150603 |